Gonadorelin and leuprolide are both derived from gonadotropin-releasing hormone (GnRH), and both act on the same pituitary receptor. That similarity leads to a common point of confusion, because in practice the two are used to produce opposite effects on the body's reproductive hormone system. The difference comes down almost entirely to how each one is dosed.

Mechanism: Pulses Versus Constant Exposure

As covered in this site's gonadorelin guide, the pituitary gland's GnRH receptors respond very differently depending on whether they're exposed to short, intermittent pulses or constant, steady stimulation. Gonadorelin, when used as originally approved (as Lutrepulse), is delivered in small pulsatile doses roughly every 90 minutes through a pump, mimicking the hypothalamus's natural rhythm. That pulsing keeps the pituitary responsive and stimulates release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which is why it could induce ovulation in women whose own hypothalamus wasn't producing enough GnRH.

Leuprolide, by contrast, is formulated as a long-acting depot injection specifically to provide continuous, non-pulsatile exposure. That steady stimulation initially causes a brief surge in hormone release (sometimes called a "flare"), but within one to two weeks it desensitizes the pituitary's GnRH receptors, shutting hormone production down to near-castrate levels. Where gonadorelin's pulsatile delivery stimulates the reproductive axis, leuprolide's continuous delivery suppresses it — the same receptor, producing opposite outcomes, purely as a function of dosing pattern.

Approved Uses and Current Availability

Leuprolide (sold as Lupron Depot and in generic versions) is FDA-approved and actively marketed for conditions where shutting down sex hormone production is the goal: advanced prostate cancer, endometriosis, central precocious puberty, and uterine fibroids, among others. It remains widely available by prescription through standard pharmacy channels.

Gonadorelin's history is different. Its branded approved products — Factrel for diagnostic testing and Lutrepulse for pulsatile fertility treatment — are both discontinued in the U.S. market. Current access runs almost entirely through compounding pharmacies, most often for off-label use alongside testosterone replacement therapy to help preserve testicular function and fertility, a use that hasn't gone through the same kind of dedicated clinical trials that supported its original approvals.

Side Effects Reflect the Opposite Mechanisms

Leuprolide's side effects largely mirror what you'd expect from suppressing sex hormones: hot flashes, bone density loss with extended use, and an initial symptom flare before suppression takes hold (clinically significant enough that it's sometimes managed with an added anti-androgen in prostate cancer patients). Gonadorelin's side effect profile, tied to stimulating rather than suppressing the axis, centers more on injection-site reactions and, historically, risks associated with the Lutrepulse infusion pump device itself, since it was delivered continuously over three weeks rather than as a single depot shot.

Practical Takeaway

If you've heard both of these names in a hormone-therapy conversation and assumed they do roughly the same thing because they're both "GnRH peptides," the opposite is closer to true: leuprolide shuts the reproductive axis down, while gonadorelin, dosed correctly, stimulates it. Which one makes sense for a given patient depends entirely on the clinical goal — suppression in cancer or precocious puberty care, or stimulation in fertility and TRT-adjunct care — and that distinction is exactly the kind of thing to talk through directly with an endocrinologist, urologist, or oncologist rather than inferring from the shared "GnRH" label.